S1 Biopharma is developing first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men. The company’s non-hormonal therapies work uniquely by restoring the natural balance of neurotransmitters in the brain.

Pharmaceutical

S1 Biopharma

Nicolas G. Sitchon

John F. Kaufmann

The S1 Biopharma executive team has experience in finance and investment from companies like Laureate International Universities, Fidelity Investments, and HSBC. This experience gives them the knowledge and ability to make sound financial decisions for the company. They also have a wide range of educational backgrounds, which helps them to understand the science behind the products they are developing.

CEO and Executive Team

About

Team members

Other teams at S1 Biopharma

Board of Directors

Leadership Team